Business
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms in second half 2026 The ACR-2316 Phase 1/2 study is advancing towards expansion phase demonstrating favorable tolerability, primarily transient neutropenia, with durable clinical activity at weekly dosing regimens in subjects with AP3-prioritized tumors, including heavily pretreated lung cancers Cash
About this update from Acrivon Therapeutics, Inc.
[{"type":"image","alt":"Acrivon Therapeutics, Inc","displaySize":"","headline":null,"caption":"Acrivon Therapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/30d85aaf0ff4222a9289e1cb227420f6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/18842H0LzLmEExp9Uy8VVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/30d85aaf0ff4222a9289e1cb227420f6","width":300,"height":160},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/18842H0LzLmEExp9Uy8VVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/30d85aaf0ff4222a9289e1cb227420f6","width":300,"height":160}},"lazy":false},{"type":"text","content":"The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms in second half 2026 ","length":218,"tagName":"p"},{"type":"text","content":"The ACR-2316 Phase 1/2 study is advancing towards expansion phase demonstrating favorable tolerability, primarily transient neutropenia, with durable clinical activity at weekly dosing regimens in subjects with AP3-prioritized tumors, including heavily pretreated lung cancers ","length":276,"tagName":"p"},{"type":"text","content":"Cash, cash equivalents, and marketable securities of $97.7 million as of March 31, 2026, plus proceeds of $7.3 million from subsequent equity financing, expected to fund operations into third quarter of 2027 and through multiple anticipated clinical milestones","length":260,"tagName":"p"},{"type":"text","content":"WATERTOWN, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today reported financial results for the first quarter ended March 31, 2026 and reviewed recent business highlights.","length":515,"tagName":"p"},{"type":"text","content":"“2026 is an important catalyst year for Acrivon as we advance our two differentiated, AP3-guide...